2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Emerging Technologies, Gene Editing, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Vaccines, Gene Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Diseases, Bleeding and Clotting, Hemophilia, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

4311 Comparing efficacy and safety of prenatal versus neonatal rAAV6-TTR-FVIII(LCO) gene therapy for hemophilia A in a sheep model

Martin Rodriguez, PhD, Walaa M Mohamed, DVM2, Oluwaseun Babatunde, MS3, Bill Vaughan, PhD4, Andrew M Farland, MD5, John Owen, MD, FRCPC, MBA6, Christopher Doering, PhD7, H. Trent Spencer, PhD8, Anthony Atala, MD9, Christopher D Porada, PhD10, M. Graca Almeida-Porada, MD, PhD11
1 Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
2 Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
3 Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
4 Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
5 Special Hematology Laboratory, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
6 Special Hematology Laboratory, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
7 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States
8 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States
9 Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
10 Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
11 Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States

In recombinant adeno-associated virus (rAAV)-based gene therapy for hemophilia A (HA), the progressive decline in transgene-derived factor VIII (FVIII) expression remains a major barrier to durable therapeutic efficacy. This loss of expression is thought to result from multiple mechanisms, including immune-mediated elimination of transduced hepatocytes, impaired FVIII synthesis and secretion secondary to endoplasmic reticulum (ER) stress, and epigenetic silencing of the vector genome.  Using sheep as a model for evaluating gene therapy approaches, we showed that prenatal administration (PNGT) of  rAAV5 encoding a bioengineered, codon optimized FVIII (rAAV5-lcoET3) achieved higher levels of hepatic transduction than when rAAV5-lcoET3 was administered neonatally (NNGT).  Since studies have shown that rAAV6 not only has higher liver tropism than rAAV5 but also transduces liver endothelial cells with greater efficiency, here we compared the outcomes of PNGT and NNGT using rAAV6-TTR-lcoET3. Sheep fetuses (n=4) at 60-65 gestation days and 3 day-old neonatal lambs (n=5) received 2x1012 vg/kg rAAV6-TTR-lcoET3 intraperitoneally or via cephalic vein respectively. Circulating lcoET3 levels were detectable by ELISA up to 1 yr in both groups. At 180 days post-administration, lcoET3 in circulation reached 41.6±2.9 ng/mL and 16.7±0.7 ng/mL in the PNGT and NNGT groups respectively. dPCR to AAV2-ITR was used to determine vector biodistribution; while the PNGT group had higher VCN in liver, lung, thymus, and spleen, the NNGT group displayed higher VCN in heart, thoracic/mesenteric lymph nodes, and spleen. Stratification of hepatic transduction levels by short-term (3mo) and long-term (12-15mo) post-PNGT, demonstrated that there was no statistical difference between short-term and long-term VCN levels (p=0.34). In addition, long-term liver VCN in PNGT recipients was more than 100-fold higher than that of  NNGT recipients (PNGT VCN = 0.1, NNGT VCN = 0.001)(p<0.05). In PNGT recipients, RT-dPCR also confirmed that up to 12-15 months,  significantly higher levels of lcoET3 transcripts were found in liver when compared to lung, thymus, and spleen (p<0.001). By contrast, and at the same 12-15 month timepoint, transcripts in the liver of NNGT recipients were nearly undetectable, while no lcoET3 transcripts were identified in any other tissues. Lastly, to investigate whether rAAV6-TTR-lcoET3 triggered innate immune response and inflammation in PNGT recipients, we performed 3' mRNA-seq on liver-derived total RNA (RIN>8, all samples) at 14 days post-administration,  to evaluate alterations in differential gene expression when compared to saline-injected PNGT animals. Expression profiling is still ongoing, but preliminary findings show alterations in pathways involved in rAAV vector entry, viral response, interferon, complement, ER stress, and mitochondrial metabolism. These findings using a large animal model contribute to the understanding of AAV vector biodistribution, liver transduction efficiency, potential inflammatory responses and genotoxicities in the prenatal and neonatal setting, thus allowing for the development of safer and more effective treatments of patients with hemophilia A.

Martin Rodriguez, PhD: No relevant conflicts of interest to declare.